Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 1/20 | 0.40 |
| ▸ | CCR8 | P51685 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16597715 | 0.95 | TSHR (0.49) | TSHRMEN1KMT2AMAPK1GAA | |
| SCHEMBL16597946 | 0.95 | PARP10 (0.47) | PARP10TSHRMEN1KMT2AMAPK1 | |
| SCHEMBL18017504 | 0.89 | ALDH1A1 (0.45) | KMT2AMAPK1GPR119USP30HTT | |
| SCHEMBL22673922 | 0.84 | KMT2A (0.47) | TSHRMEN1KMT2AMAPK1GAA | |
| SCHEMBL22212902 | 0.84 | PARP10 (0.46) | PARP10TSHRMEN1KMT2AMAPK1 | |
| SCHEMBL18017499 | 0.84 | ALDH1A1 (0.53) | TSHRMEN1KMT2AMAPK1GAA | |
| SCHEMBL22673718 | 0.84 | HPGD (0.48) | TSHRMEN1KMT2AMAPTRAB9A | |
| SCHEMBL16597721 | 0.83 | STS (0.44) | PARP10TSHRMEN1KMT2AMAPK1 | |
| SCHEMBL18017523 | 0.83 | GPR119 (0.45) | KMT2AMAPK1RAB9AGPR119USP30 | |
| SCHEMBL16598019 | 0.80 | STS (0.48) | PARP10MEN1KMT2AMAPK1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059176-A1 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK FOR TREATING CANCER | GUANGZHOU INNOCARE PHARMA TECH CO LTD (CN) | 2025-02-20 | — | — | US | disclosed |
| US-12162873-B2 | Substituted nicotinimide inhibitors of BTK for treating cancer | GUANGZHOU INNOCARE PHARMA TECH CO., LTD. (CN) | 2024-12-10 | — | — | US | disclosed |
| US-20240101545-A1 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK FOR TREATING CANCER | GUANGZHOU INNOCARE PHARMA TECH CO LTD (CN) | 2024-03-28 | — | — | US | disclosed |
| US-11840513-B2 | Substituted nicotinimide inhibitors of BTK for treating cancer | Guangzhou Innocare Pharma Tech Co., Ltd (CN) | 2023-12-12 | — | — | US | disclosed |
| US-11840513-B2 | Substituted nicotinimide inhibitors of BTK for treating cancer | Guangzhou Innocare Pharma Tech Co., Ltd (CN) | 2023-12-12 | — | — | US | disclosed |
| US-11840513-B2 | Substituted nicotinimide inhibitors of BTK for treating cancer | Guangzhou Innocare Pharma Tech Co., Ltd (CN) | 2023-12-12 | — | — | US | disclosed |
| US-20220298153-A1 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK FOR TREATING CANCER | GUANGZHOU INNOCARE PHARMA TECH CO LTD (CN) | 2022-09-22 | — | — | US | disclosed |
| US-20220298153-A1 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK FOR TREATING CANCER | GUANGZHOU INNOCARE PHARMA TECH CO LTD (CN) | 2022-09-22 | — | — | US | disclosed |
| US-11345695-B2 | Substituted nicotinimide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune disease | GUANGZHOU INNOCARE PHARMA TECH CO., LTD. (CN) | 2022-05-31 | — | — | US | disclosed |
| US-11345695-B2 | Substituted nicotinimide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune disease | GUANGZHOU INNOCARE PHARMA TECH CO., LTD. (CN) | 2022-05-31 | — | — | US | disclosed |
| US-20190276446-A1 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK AND THEIR PREPARATION AND USE IN THE TREATMENT OF CANCER, INFLAMMATION AND AUTOIMMUNE DISEASE | GUANGZHOU INNOCARE PHARMA TECH CO LTD (CN) | 2019-09-12 | — | — | US | disclosed |
| US-10301297-B2 | Substituted nicotinimide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune disease | GUANGZHOU INNOCARE PHARMA TECH CO., LTD. (CN) | 2019-05-28 | — | — | US | disclosed |
| US-10301297-B2 | Substituted nicotinimide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune disease | GUANGZHOU INNOCARE PHARMA TECH CO., LTD. (CN) | 2019-05-28 | — | — | US | disclosed |
| US-20180222897-A1 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK AND THEIR PREPARATION AND USE IN THE TREATMENT OF CANCER, INFLAMMATION AND AUTOIMMUNE DISEASE | GUANGZHOU INNOCARE PHARMA TECH CO., LTD. (CN) | 2018-08-09 | — | — | US | disclosed |
| US-20180222897-A1 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK AND THEIR PREPARATION AND USE IN THE TREATMENT OF CANCER, INFLAMMATION AND AUTOIMMUNE DISEASE | GUANGZHOU INNOCARE PHARMA TECH CO., LTD. (CN) | 2018-08-09 | — | — | US | disclosed |
| US-9951056-B2 | Substituted nicotinamide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune disease | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2018-04-24 | — | — | US | disclosed |
| US-20160237075-A1 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK AND THEIR PREPARATION AND USE IN THE TREATMENT OF CANCER, INFLAMMATION AND AUTOIMMUNE DISEASE | GUANGZHOU INNOCARE PHARMA TECH CO., LTD. (CN) | 2016-08-18 | — | — | US | disclosed |
| EP-3052476-A2 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK AND THEIR PREPARATION AND USE IN THE TREATMENT OF CANCER, INFLAMMATION AND AUTOIMMUNE DISEASE | Beijing Synercare Pharma Tech Co., Ltd. (CN) | 2016-08-10 | — | — | EP | disclosed |
| WO-2015048662-A2 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK AND THEIR PREPARATION AND USE IN THE TREATMENT OF CANCER, INFLAMMATION AND AUTOIMMUNE DISEASE | X-RX DISCOVERY, INC. (US) | 2015-04-02 | — | — | WO | disclosed |
| WO-2015048662-A2 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK AND THEIR PREPARATION AND USE IN THE TREATMENT OF CANCER, INFLAMMATION AND AUTOIMMUNE DISEASE | X-RX DISCOVERY, INC. (US) | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237075-A1 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK AND THEIR PREPARATION AND USE IN THE TREATMENT OF CANCER, INFLAMMATION AND AUTOIMMUNE DISEASE | BTK, SYK, LYN | PARP10 851/4885TSHR 1826/4885MEN1 1269/4885 |
| US-20190276446-A1 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK AND THEIR PREPARATION AND USE IN THE TREATMENT OF CANCER, INFLAMMATION AND AUTOIMMUNE DISEASE | BTK, SYK, LYN | PARP10 851/4885TSHR 1826/4885MEN1 1269/4885 |
| US-20180222897-A1 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK AND THEIR PREPARATION AND USE IN THE TREATMENT OF CANCER, INFLAMMATION AND AUTOIMMUNE DISEASE | BTK, SYK, LYN | PARP10 851/4885TSHR 1826/4885MEN1 1269/4885 |
| US-11345695-B2 | Substituted nicotinimide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune disease | BTK, SYK, LYN | PARP10 851/4885TSHR 1826/4885MEN1 1269/4885 |
| US-10301297-B2 | Substituted nicotinimide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune disease | BTK, SYK, LYN | PARP10 851/4885TSHR 1826/4885MEN1 1269/4885 |
| US-20220298153-A1 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK FOR TREATING CANCER | BTK, SYK, LYN | PARP10 741/4885TSHR 2226/4885MEN1 1692/4885 |
| US-20250059176-A1 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK FOR TREATING CANCER | BTK, SYK, LYN | PARP10 741/4885TSHR 2226/4885MEN1 1692/4885 |
| US-20240101545-A1 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK FOR TREATING CANCER | BTK, SYK, LYN | PARP10 741/4885TSHR 2226/4885MEN1 1692/4885 |
| US-12162873-B2 | Substituted nicotinimide inhibitors of BTK for treating cancer | BTK, SYK, LYN | PARP10 741/4885TSHR 2226/4885MEN1 1692/4885 |
| US-11840513-B2 | Substituted nicotinimide inhibitors of BTK for treating cancer | BTK, SYK, LYN | PARP10 741/4885TSHR 2226/4885MEN1 1692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.